Literature DB >> 21441461

Cross-protective TH1 immunity against Aspergillus fumigatus and Candida albicans.

Claudia Stuehler1, Nina Khanna, Silvia Bozza, Teresa Zelante, Silvia Moretti, Michaela Kruhm, Sarah Lurati, Barbara Conrad, Eike Worschech, Stefan Stevanović, Sven Krappmann, Hermann Einsele, Jean-Paul Latgé, Juergen Loeffler, Luigina Romani, Max S Topp.   

Abstract

T cell-mediated heterologous immunity to different pathogens is promising for the development of immunotherapeutic strategies. Aspergillus fumigatus and Candida albicans, the 2 most common fungal pathogens causing severe infections in immunocompromised patients, are controlled by CD4+ type 1 helper T (T(H)1) cells in humans and mice, making induction of fungus-specific CD4+ T(H)1 immunity an appealing strategy for antifungal therapy. We identified an immunogenic epitope of the A fumigatus cell wall glucanase Crf1 that can be presented by 3 common major histocompatibility complex class II alleles and that induces memory CD4+ T(H)1 cells with a diverse T-cell receptor repertoire that is cross-reactive to C albicans. In BALB/c mice, the Crf1 protein also elicits cross-protection against lethal infection with C albicans that is mediated by the same epitope as in humans. These data illustrate the existence of T cell-based cross-protection for the 2 distantly related clinically relevant fungal pathogens that may foster the development of immunotherapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21441461     DOI: 10.1182/blood-2010-12-325084

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  43 in total

Review 1.  Immunotherapy for viral and fungal infections.

Authors:  H Einsele; J Löffler; M Kapp; L Rasche; S Mielke; U G Grigoleit
Journal:  Bone Marrow Transplant       Date:  2015-06       Impact factor: 5.483

Review 2.  Immune responses to invasive aspergillosis: new understanding and therapeutic opportunities.

Authors:  Tobias M Hohl
Journal:  Curr Opin Infect Dis       Date:  2017-08       Impact factor: 4.915

Review 3.  Universal fungal vaccines: could there be light at the end of the tunnel?

Authors:  Mawieh Hamad
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

Review 4.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

5.  Host response to pulmonary fungal infections: A highlight on cell-driven immunity to Cryptococcus species and Aspergillus fumigatus.

Authors:  Orchi Dutta; Jorge A Masso-Silva; Keyi Wang; Amariliz Rivera
Journal:  Curr Pharmacol Rep       Date:  2017-10-14

Review 6.  Dendritic cells in antifungal immunity and vaccine design.

Authors:  René M Roy; Bruce S Klein
Journal:  Cell Host Microbe       Date:  2012-05-17       Impact factor: 21.023

Review 7.  Immunity to fungi.

Authors:  Salomé LeibundGut-Landmann; Marcel Wüthrich; Tobias M Hohl
Journal:  Curr Opin Immunol       Date:  2012-05-19       Impact factor: 7.486

Review 8.  Vaccine immunity against fungal infections.

Authors:  Som G Nanjappa; Bruce S Klein
Journal:  Curr Opin Immunol       Date:  2014-03-03       Impact factor: 7.486

Review 9.  Fungus-Specific CD4 T Cells as Specific Sensors for Identification of Pulmonary Fungal Infections.

Authors:  Alexander Scheffold; Carsten Schwarz; Petra Bacher
Journal:  Mycopathologia       Date:  2017-11-22       Impact factor: 2.574

10.  Induction of A. fumigatus-specific CD4-positive T cells in patients recovering from invasive aspergillosis.

Authors:  Hetty Jolink; Renate S Hagedoorn; Ellen L Lagendijk; Jan W Drijfhout; Jaap T van Dissel; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Haematologica       Date:  2014-04-18       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.